GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.
Boston Scientific Co. (NYSE:BSX – Get Free Report) has been given an average recommendation of “Buy” by the twenty-three ...
Within Neuromodulation, Boston Scientific’s pain business is consistently gaining traction, banking on strength in Spinal cord stimulation (SCS), driven by its innovative Alpha portfolio with ...
Boston Scientific (NYSE:BSX – Get Free Report) had its price objective hoisted by research analysts at Stifel Nicolaus from ...
Boston Scientific Corporation develops ... neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency ...